Oral ATR kinase inhibitorAstraZeneca

Ceralasertib

Ceralasertib is an oral ATR kinase inhibitor that targets the DNA-damage response in cancer cells. AstraZeneca evaluated it in combination with the checkpoint inhibitor durvalumab in previously treated NSCLC (the LATIFY study).

Also known as: AZD6738

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Indications

Targets

Ceralasertib forecasting benchmarks

1 benchmark

ResolvedPhase 3

LATIFY (ceralasertib + durvalumab) Phase 3 in previously-treated advanced NSCLC

Ceralasertib · Non-small cell lung cancer

Dec 22, 2025Clinical Trials

Mechanism & molecular targets

ATR· gene

Indications studied

Non-small cell lung cancer· NSCLC

Developed by

AstraZeneca· AZN

About Ceralasertib

What is Ceralasertib?

What does Ceralasertib target?

Ceralasertib acts on ATR kinase.

How well do AI models predict Ceralasertib trial outcomes?

Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.